Banting lecture 2009: An unfinished journey: Molecular pathogenesis to prevention of type 1A diabetes

Diabetes

Volumn 59, Issue 4, 2010, Pages 759-774

  Eisenbarth, George S ^a  

^a UNIVERSITY OF COLORADO DENVER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; B LYMPHOCYTE ANTIBODY; CD20 ANTIBODY; GLUTAMATE DECARBOXYLASE 65 ANTIBODY; INSULIN; INSULIN ANTIBODY; INSULIN DERIVATIVE; INSULIN PEPTIDE B: 9 23; NICOTINAMIDE; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 22; PLACEBO; SULFONYLUREA; T LYMPHOCYTE RECEPTOR; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANTIBODY DETECTION; AUTOIMMUNE POLYENDOCRINOPATHY CANDIDIASIS ECTODERMAL DYSTROPHY; AUTOIMMUNITY; CELL CLONE; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE COURSE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; GENE DELETION; GENE EXPRESSION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC SUSCEPTIBILITY; HIGH RISK POPULATION; HLA SYSTEM; HUMAN; IMMUNE RESPONSE; IMMUNOCYTOCHEMISTRY; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INNATE IMMUNITY; INSULIN DEPENDENCE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN HYPOGLYCEMIA; INSULIN TREATMENT; INSULITIS; INTRAVENOUS GLUCOSE TOLERANCE TEST; IPEX SYNDROME; KETOACIDOSIS; LYMPHOMA; MAJOR HISTOCOMPATIBILITY COMPLEX; METABOLIC DISORDER; MOLECULAR MECHANICS; MULTIPLE SCLEROSIS; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS ISLET TRANSPLANTATION; PATIENT CARE; PHENOTYPE; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; T LYMPHOCYTE; VITILIGO;

DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 1; DISEASE PROGRESSION; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HLA ANTIGENS; HUMANS; INSULIN; POLYMORPHISM, GENETIC; RISK FACTORS; SIBLINGS;

EID: 77951169178     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db09-1855     Document Type: Review

References (185)

1. Rewers A, Klingensmith G, Davis C, Petitti DB, Pihoker C, Rodriguez B, Schwartz ID, Imperatore G, Williams D, Dolan LM, Dabelea D. Presence of diabetic ketoacidosis at diagnosis of diabetes mellitus in youth: the Search for Diabetes in Youth Study. Pediatrics 2008;121:e1258-e1266
2. Dahlquist G, Källén B. Mortality in childhood-onset type 1 diabetes: a population-based study. Diabetes Care 2005;28:2384-2387 (Pubitemid 41384281)
3. Makinen VP, Forsblom C, Thorn LM, Waden J, Kaski K, Ala-Korpela M, Groop PH. Network of vascular diseases, death and biochemical characteristics in a set of 4,197 patients with type 1 diabetes (The FinnDiane Study). Cardiovasc Diabetologia 2009;8:54
4. Tamborlane WV, Beck RW. Continuous glucose monitoring in type 1 diabetes mellitus. Lancet 2009;373:1744-1746
5. Garg SK, Kelly WC, Voelmle MK, Ritchie PJ, Gottlieb PA, McFann KK, Ellis SL. Continuous home monitoring of glucose: improved glycemic control with real-life use of continuous glucose sensors in adult subjects with type 1 diabetes. Diabetes Care 2007;30:3023-3025
6. Wadwa RP, Fiallo-Scharer R, Vanderwel B, Messer LH, Cobry E, Chase HP. Continuous glucose monitoring in youth with type 1 diabetes. Diabetes Technol Ther 2009;1(Suppl. 11):S83-S91
7. Kandaswamy R, Sutherland DE. Pancreas versus islet transplantation in diabetes mellitus: How to allocate deceased donor pancreata? Transplant Proc 2006;38:365-367
8. Nanji SA, Shapiro AM. Advances in pancreatic islet transplantation in humans. Diabetes Obes Metab 2006;8:15-25
9. Shapiro AM, Ricordi C, Hering BJ, Auchincloss H, Lindblad R, Robertson RP, Secchi A, Brendel MD, Berney T, Brennan DC, Cagliero E, Alejandro R, Ryan EA, DiMercurio B, Morel P, Polonsky KS, Reems JA, Bretzel RG, Bertuzzi F, Froud T, Kandaswamy R, Sutherland DE, Eisenbarth G, Segal M, Preiksaitis J, Korbutt GS, Barton FB, Viviano L, Seyfert-Margolis V, Bluestone J, Lakey JR. International trial of the Edmonton protocol for islet transplantation. N Engl J Med 2006;355:1318-1330 (Pubitemid 44465460)
10. Laughlin E, Burke G, Pugliese A, Falk B, Nepom G. Recurrence of autoreactive antigen-specific CD4+ T cells in autoimmune diabetes after pancreas transplantation. Clin Immunol 2008;128:23-30
11. Nakayama M, Abiru N, Moriyama H, Babaya N, Liu E, Miao D, Yu L, Wegmann DR, Hutton JC, Elliott JF, Eisenbarth GS. Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice. Nature 2005;435:220-223 (Pubitemid 40685949)
12. Hattori M, Buse JB, Jackson RA, Glimcher L, Dorf ME, Minami M, Makino S, Moriwaki K, Kuzuya H, Imura H, Seidman JG, Eisenbarth, GS. The NOD mouse: recessive diabetogenic gene in the major histocompatibility complex. Science 1986;231:733-735 (Pubitemid 16104046)
13. Kobayashi M, Jasinski J, Liu E, Li M, Miao D, Zhang L, Yu L, Nakayama M, Eisenbarth GS. Conserved T cell receptor alpha-chain induces insulin autoantibodies. Proc Natl Acad Sci U S A 2008;105:10090-10094
14. Homann D, Eisenbarth GS. An immunologic homunculus for type 1 diabetes. J Clin Invest 2006;116:1212-1215
15. Krishnamurthy B, Dudek NL, McKenzie MD, Purcell AW, Brooks AG, Gellert S, Colman PG, Harrison LC, Lew AM, Thomas HE, Kay TW. Responses against islet antigens in NOD mice are prevented by tolerance to proinsulin but not IGRP. J Clin Invest 2006;116:3258-3265 (Pubitemid 44878640)
16. Jaeckel E, Lipes MA, von Boehmer H. Recessive tolerance to preproinsulin 2 reduces but does not abolish type 1 diabetes. Nat Immunol 2004;5:1028-1035 (Pubitemid 41057722)
17. Thébault-Baumont K, Dubois-Laforgue D, Krief P, Briand JP, Halbout P, Vallon-Geoffroy K, Morin J, Laloux V, Lehuen A, Carel JC, Jami J, Muller S, Boitard C. Acceleration of type 1 diabetes mellitus in proinsulin 2-deficient NOD mice. J Clin Invest 2003;111:851-857 (Pubitemid 37074960)
18. Fukushima K, Abiru N, Nagayama Y, Kobayashi M, Satoh T, Nakahara M, Kawasaki E, Yamasaki H, Ueha S, Matsushima K, Liu E, Eguchi K. Combined insulin B:9-23 self-peptide and polyinosinic-polycytidylic acid accelerate insulitis but inhibit development of diabetes by increasing the proportion of CD4+Foxp3+ regulatory T cells in the islets in non-obese diabetic mice. Biochem Biophys Res Commun 2008;367:719-724
19. Solvason N, Lou YP, Peters W, Evans E, Martinez J, Ramirez U, Ocampo A, Yun R, Ahmad S, Liu E, Yu L, Eisenbarth G, Leviten M, Steinman L, Garren H. Improved efficacy of a tolerizing DNA vaccine for reversal of hyperglycemia through enhancement of gene expression and localization to intracellular sites. J Immunol 2008;181:8298-8307
20. Suri A, Levisetti MG, Unanue ER. Do the peptide-binding properties of diabetogenic class II molecules explain autoreactivity? Curr Opin Immunol 2008;20:105-110
21. Du W, Wong FS, Li MO, Peng J, Qi H, Flavell RA, Sherwin R, Wen L. TGF-beta signaling is required for the function of insulin-reactive T regulatory cells. J Clin Invest 2006;116:1360-1370
22. Wegmann DR, Norbury-Glaser M, Daniel D. Insulin-specific T cells are a predominant component of islet infiltrates in pre-diabetic NOD mice. Eur J Immunol 1994;24:1853-1857 (Pubitemid 24237557)
23. Daniel D, Gill RG, Schloot N, Wegmann D. Epitope specificity, cytokine production profile and diabetogenic activity of insulin-specific T cell clones isolated from NOD mice. Eur J Immunol 1995;25:1056-1062
24. Tsai S, Shameli A, Santamaria P. CD8+ T cells in type 1 diabetes. Adv Immunol 2008;100:79-124
25. Wong FS, Karttunen J, Dumont C, Wen L, Visintin I, Pilip IM, Shastri N, Pamer EG, Janeway CA Jr. Identification of an MHC class I-restricted autoantigen in type 1 diabetes by screening an organ-specific cDNA library. Nat Med 1999;5:1026-1031 (Pubitemid 29439573)
26. DiLorenzo TP, Serreze DV: The good turned ugly: immunopathogenic basis for diabetogenic CD8+ T cells in NOD mice. Immunol Rev 2005;204:250-263
27. Moriyama H, Abiru N, Paronen J, Sikora K, Liu E, Miao D, Devendra D, Beilke J, Gianani R, Gill RG, Eisenbarth GS. Evidence for a primary islet autoantigen (preproinsulin 1) for insulitis and diabetes in the nonobese diabetic mouse. Proc Natl Acad Sci U S A 2003;100:10376-10381 (Pubitemid 37071886)
28. Yamamoto T, Yamato E, Tashiro F, Sato T, Noso S, Ikegami H, Tamura S, Yanagawa Y, Miyazaki JI. Development of autoimmune diabetes in glutamic acid decarboxylase 65 (GAD65) knockout NOD mice. Diabetologia 2004;47:221-224 (Pubitemid 38315358)
29. Kubosaki A, Miura J, Notkins AL. IA-2 is not required for the development of diabetes in NOD mice. Diabetologia 2004;47:149-150 (Pubitemid 38141956)
30. Kubosaki A, Gross S, Miura J, Saeki K, Zhu M, Nakamura S, Hendriks W, Notkins AL. Targeted disruption of the IA-2beta gene causes glucose intolerance and impairs insulin secretion but does not prevent the development of diabetes in NOD mice. Diabetes 2004;53:1684-1691 (Pubitemid 38857025)
31. Brimnes MK, Bonifaz L, Steinman RM, Moran TM. Influenza virus-induced dendritic cell maturation is associated with the induction of strong T cell immunity to a coadministered, normally nonimmunogenic protein. J Exp Med 2003;198:133-144 (Pubitemid 36870193)
32. Nakayama M, Beilke JN, Jasinski JM, Kobayashi M, Miao D, Li M, Coulombe MG, Liu E, Elliott JF, Gill RG, Eisenbarth GS. Priming and effector dependence on insulin B:9-23 peptide in NOD islet autoimmunity. J Clin Invest 2007;117:1835-1843 (Pubitemid 47036317)
33. Krishnamurthy B, Mariana L, Gellert SA, Colman PG, Harrison LC, Lew AM, Santamaria P, Thomas HE, Kay TW. Autoimmunity to both proinsulin and IGRP is required for diabetes in nonobese diabetic 8.3 TCR transgenic mice. J Immunol 2008;180:4458-4464
34. Kim SK, Tarbell KV, Sanna M, Vadeboncoeur M, Warganich T, Lee M, Davis M, McDevitt HO. Prevention of type I diabetes transfer by glutamic acid decarboxylase 65 peptide 206-220-specific T cells. Proc Natl Acad Sci U S A 2004;101:14204-14209 (Pubitemid 39305054)
35. Stadinski BD, Delong T, Reisdorph N, Reisdorph R, Powell RL, Armstrong M, Piganelli JD, Barbour G, Bradley B, Crawford F, Marrack P, Mahata SK, Kappler JW, Haskins K. Chromogranin A is an autoantigen in type 1 diabetes. Nat Immunol 2010;11:225-231
36. Han B, Serra P, Amrani A, Yamanouchi J, Marée AF, Edelstein-Keshet L, Santamaria P. Prevention of diabetes by manipulation of anti-IGRP autoimmunity: high efficiency of a low-affinity peptide. Nat Med 2005;11: 645-652 (Pubitemid 40868305)
37. Pop SM, Wong CP, He Q, Wang Y, Wallet MA, Goudy KS, Tisch R. The type and frequency of immunoregulatory CD4+ T cells govern the efficacy of antigen-specific immunotherapy in nonobese diabetic mice. Diabetes 2007;56:1395-1402 (Pubitemid 46715604)
38. Mukherjee R, Chaturvedi P, Qin HY, Singh B. CD4+CD25+ regulatory T cells generated in response to insulin B:9-23 peptide prevent adoptive transfer of diabetes by diabetogenic T cells. J Autoimmun 2003;21:221-237 (Pubitemid 37410111)
39. Tang Q, Bluestone JA. The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat Immunol 2008;9:239-244 (Pubitemid 351267321)
40. Kanazawa Y, Shimada A, Oikawa Y, Okubo Y, Tada A, Imai T, Miyazaki J, Itoh H. Induction of anti-whole GAD65 reactivity in vivo results in disease suppression in type 1 diabetes. J Autoimmun 2009;32:104-109
41. Bresson D, Togher L, Rodrigo E, Chen Y, Bluestone JA, Herold KC, von Herrath M. Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. J Clin Invest 2006;116:1371-1381
42. Ablamunits V, Bisikirska BC, Herold KC. Human regulatory CD8 T cells. Ann N Y Acad Sci 2008;1150:234-238
43. Hu CY, Rodriguez-Pinto D, Du W, Ahuja A, Henegariu O, Wong FS, Shlomchik MJ, Wen L. Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice. J Clin Invest 2007;117:3857-3867 (Pubitemid 350224095)
44. Simone EA, Wegmann DR, Eisenbarth GS. Immunologic "vaccination" for the prevention of autoimmune diabetes mellitus (type 1A). Diabetes Care 1999;22(Suppl. 2):B7-B15
45. Kobayashi M, Abiru N, Arakawa T, Fukushima K, Zhou H, Kawasaki E, Yamasaki H, Liu E, Miao D, Wong FS, Eisenbarth GS, Eguchi K. Altered B:9 23 insulin, when administered intranasally with cholera toxin adjuvant, suppresses the expression of insulin autoantibodies and prevents diabetes. J Immunol 2007;179:2082-2088
46. Abiru N, Yu L, Wegmann D, Eisenbarth GS: Induction of autoantibodies to native insulin in normal and NOD derived mice following immunization with the immunodominant self-B-chain insulin peptide B:9-23 (Abstract). Diabetes 2000;49(Suppl. 1):A232
47. Abiru N, Maniatis AK, Yu L, Miao D, Moriyama H, Wegmann D, Eisenbarth GS. Peptide and MHC specific breaking of humoral tolerance to native insulin with the B:9-23 peptide in diabetes prone and normal mice. Diabetes 2001;50:1274-1281 (Pubitemid 32500159)
48. Devendra D, Miao D, Nakayama M, Eisenbarth GS, Liu E: Pancreatic autoimmunity induction with insulin B:9-23 peptide and viral mimics in the NZB mouse. Ann N Y Acad Sci 2006;1079:135-137 (Pubitemid 44968713)
49. Eisenbarth SG, Homann D. Primer immunology and autoimmunity. In Type I Diabetes: Molecular, Cellular and Clinical Immunology [article online], 2009. Available from http://www.uchsc.edu/misc/diabetes/books. html. Accessed 20 February 2010
50. Pietropaolo M, Surhigh JM, Nelson PW, Eisenbarth GS. Primer: immunity and autoimmunity. Diabetes 2008;57:2872-2882
51. Erlich H, Valdes AM, Noble J, Carlson JA, Varney M, Concannon P, Mychaleckyj JC, Todd JA, Bonella P, Fear AL, Lavant E, Louey A, Moonsamy P, Type 1 Diabetes Genetics Consortium. HLA DR-DQ haplotypes and genotypes and type 1 diabetes risk: analysis of the Type 1 Diabetes Genetics Consortium families. Diabetes 2008;57:1084-1092
52. Wallis RH, Wang K, Marandi L, Hsieh E, Ning T, Chao GY, Sarmiento J, Paterson AD, Poussier P. Type 1 diabetes in the BB rat: a polygenic disease. Diabetes 2009;58:1007-1017
53. Todd JA, Acha-Orbea H, Bell JI, Chao N, Fronek Z, Jacob CO, McDermott M, Sinha AA, Timmerman L, Steinman L. A molecular basis for MHC class II-associated autoimmunity. Science 1988;240:1003-1009
54. Corper AL, Stratmann T, Apostolopoulos V, Scott CA, Garcia KC, Kang AS, Wilson IA, Teyton L. A structural framework for deciphering the link between I-Ag7 and autoimmune diabetes. Science 2000;288:505-511 (Pubitemid 30236031)
55. Simone E, Daniel D, Schloot N, Gottlieb P, Babu S, Kawasaki E, Wegmann D, Eisenbarth GS. T cell receptor restriction of diabetogenic autoimmune NOD T cells. Proc Natl Acad Sci U S A 1997;94:2518-2521 (Pubitemid 27136907)
56. Burton AR, Vincent E, Arnold PY, Lennon GP, Smeltzer M, Li CS, Haskins K, Hutton J, Tisch RM, Sercarz EE, Santamaria P, Workman CJ, Vignali DA. On the pathogenicity of autoantigen-specific T cell receptors. Diabetes 2008;57:1321-1330
57. Zhang L, Jasinski JM, Kobayashi M, Davenport B, Johnson K, Davidson H, Nakayama M, Haskins K, Eisenbarth GS: Analysis of T cell receptor beta chains that combine with dominant conserved TRAV5D-4*04 anti-insulin B:9-23 alpha chains. J Autoimmun 2009;33:42-49
58. Wicker LS, Clark J, Fraser HI, Garner VE, Gonzalez-Munoz A, Healy B, Howlett S, Hunter K, Rainbow D, Rosa RL, Smink LJ, Todd JA, Peterson LB: Type 1 diabetes genes and pathways shared by humans and NOD mice. J Autoimmun 2005;25(Suppl.):29-33 (Pubitemid 41728041)
59. Rainbow DB, Esposito L, Howlett SK, Hunter KM, Todd JA, Peterson LB, Wicker LS. Commonality in the genetic control of type 1 diabetes in humans and NOD mice: variants of genes in the IL-2 pathway are associated with autoimmune diabetes in both species. Biochem Soc Trans 2008;36:312-315 (Pubitemid 351839322)
60. Hernández Prada JA, Ferreira AJ, Katovich MJ, Shenoy V, Qi Y, Santos RA, Castellano RK, Lampkins AJ, Gubala V, Ostrov DA, Raizada MK. Structure-based identification of small-molecule angiotensin-converting enzyme 2 activators as novel antihypertensive agents. Hypertension 2008;51:1312-1317 (Pubitemid 351555943)
61. Eisenbarth GS. Type I diabetes mellitus: a chronic autoimmune disease. N Engl J Med 1986;314:1360-1368 (Pubitemid 16122469)
62. Atkinson MA, Eisenbarth GS. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 2001;358:221-229 (Pubitemid 32718550)
63. Redondo MJ, Jeffrey J, Fain PR, Eisenbarth GS, Orban T. Concordance for islet autoimmunity among monozygotic twins. N Engl J Med 2008;359: 2849-2850
64. Verge CF, Gianani R, Kawasaki E, Yu L, Pietropaolo M, Jackson RA, Chase HP, Eisenbarth GS. Prediction of type I diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies. Diabetes 1996;45:926-933
65. Achenbach P, Schlosser M, Williams AJ, Yu L, Mueller PW, Bingley PJ, Bonifacio E. Combined testing of antibody titer and affinity improves insulin autoantibody measurement: Diabetes Antibody Standardization Program. Clin Immunol 2007;122:85-90 (Pubitemid 46026696)
66. Bingley PJ, Mahon JL, Gale EA, European Nicotinamide Diabetes Intervention Trial Group. Insulin resistance and progression to type 1 diabetes in the European Nicotinamide Diabetes Intervention Trial (ENDIT). Diabetes Care 2008;31:146-150
67. Skyler JS, Krischer JP, Wolfsdorf J, Cowie C, Palmer JP, Greenbaum C, Cuthbertson D, Rafkin-Mervis LE, Chase HP, Leschek E. Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial-Type 1. Diabetes Care 2005;28:1068-1076 (Pubitemid 40616615)
68. Hagopian WA, Lernmark A, Rewers MJ, Simell OG, She JX, Ziegler AG, Krischer JP, Akolkar B: TEDDY-The Environmental Determinants of Diabetes in the Young: an observational clinical trial. Ann N Y Acad Sci 2006;1079:320-326 (Pubitemid 44968741)
69. Perheentupa J. Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. J Clin Endocrinol Metab 2006;91:2843-2850
70. Eisenbarth GS, Gottlieb PA. Autoimmune polyendocrine syndromes. N Engl J Med 2004;350:2068-2079
71. Bacchetta R, Passerini L, Gambineri E, Dai M, Allan SE, Perroni L, Dagna-Bricarelli F, Sartirana C, Matthes-Martin S, Lawitschka A, Azzari C, Ziegler SF, Levings MK, Roncarolo MG. Defective regulatory and effector T cell functions in patients with FOXP3 mutations. J Clin Invest 2006;116: 1713-1722 (Pubitemid 43911026)
72. Rao A, Kamani N, Filipovich A, Lee SM, Davies SM, Dalal J, Shenoy S. Successful bone marrow transplantation for IPEX syndrome after reduced-intensity conditioning. Blood 2007;109:383-385 (Pubitemid 46053081)
73. Su MA, Giang K, Zumer K, Jiang H, Oven I, Rinn JL, Devoss JJ, Johannes KP, Lu W, Gardner J, Chang A, Bubulya P, Chang HY, Peterlin BM, Anderson MS. Mechanisms of an autoimmunity syndrome in mice caused by a dominant mutation in Aire. J Clin Invest 2008;118:1712-1726 (Pubitemid 351632375)
74. Anderson MS, Venanzi ES, Klein L, Chen Z, Berzins SP, Turley SJ, von Boehmer H, Bronson R, Dierich A, Benoist C, Mathis D. Projection of an immunological self shadow within the thymus by the aire protein. Science 2002;298:1395-1401 (Pubitemid 35346134)
75. Kont V, Laan M, Kisand K, Merits A, Scott HS, Peterson P. Modulation of Aire regulates the expression of tissue-restricted antigens. Molecular Immunology 2008;45:25-33 (Pubitemid 47331653)
76. Meloni A, Furcas M, Cetani F, Marcocci C, Falorni A, Perniola R, Pura M, Bøe Wolff AS, Husebye ES, Lilic D, Ryan KR, Gennery AR, Cant AJ, Abinun M, Spickett GP, Arkwright PD, Denning D, Costigan C, Dominguez M, McConnell V, Willcox N, Meager A. Autoantibodies against type I interferons as an additional diagnostic criterion for autoimmune polyendocrine syndrome type I. J Clin Endocrinol Metab 2008;93:4389-4397 (Pubitemid 352789536)
77. Adamson KA, Cheetham TD, Kendall-Taylor P, Seckl JR, Pearce SH. The role of the IDDM2 locus in the susceptibility of UK APS1 subjects to type 1 diabetes mellitus. Int J Immunogenet 2007;34:17-21 (Pubitemid 46232337)
78. Maruyama T, Shimada A, Kasuga A, Kasatani T, Ozawa Y, Ishii M, Takei I, Suzuki Y, Kobayashi A, Takeda S: Analysis of MHC class II antigens in Japanese IDDM by a novel HLA-typing method, hybridization protection assay. Diabetes Res Clin Pract 1994;23:77-84 (Pubitemid 24160216)
79. Nerup J. Addison's disease - clinical studies: a report of 108 cases. Acta Endocrinol 1974;76:127-141
80. Betterle C, Lazzarotto F, Presotto F. Autoimmune polyglandular syndrome type 2: the tip of an iceberg? Clin Exp Immunol 2004;137:225-233
81. Yu L, Brewer KW, Gates S, Wu A, Wang T, Babu SR, Gottlieb PA, Freed BM, Noble J, Erlich HA, Rewers MJ, Eisenbarth GS. DRB1*04 and DQ alleles: expression of 21-hydroxylase autoantibodies and risk of progression to Addison's disease. J Clin Endocrinol Metab 1999;84:328-335 (Pubitemid 29036722)
82. Myhre AG, Undlien DE, Løvås K, Uhlving S, Nedrebø BG, Fougner KJ, Trovik T, Sørheim JI, Husebye ES. Autoimmune adrenocortical failure in Norway: Autoantibodies and HLA class II associations related to clinical features. J Clin Endocrinol Metab 2002;87:618-623
83. Barker JM. Clinical review: Type 1 diabetes-associated autoimmunity: natural history, genetic associations, and screening. J Clin Endocrinol Metab 2006;91:1210-1217
84. Barker JM. Clinical review: Type 1 diabetes-associated autoimmunity: natural history, genetic associations and screening. J Clin Endocrinol Metab 2006;91:1210-1217
85. Concannon P, Rich SS, Nepom GT. Genetics of type 1A diabetes. N Engl J Med 2009;360:1646-1654
86. Hulbert EM, Smink LJ, Adlem EC, Allen JE, Burdick DB, Burren OS, Cassen VM, Cavnor CC, Dolman GE, Flamez D, Friery KF, Healy BC, Killcoyne SA, Kutlu B, Schuilenburg H, Walker NM, Mychaleckyj J, Eizirik DL, Wicker LS, Todd JA, Goodman N. T1DBase: integration and presentation of complex data for type 1 diabetes research. Nucleic Acid Res 2007;35:D742-D746
87. Redondo MJ, Fain PR, Krischer JP, Yu L, Cuthbertson D, Winter WE, Eisenbarth GS, DPT-1 Study Group. Expression of beta-cell autoimmunity does not differ between potential dizygotic twins and siblings of patients with type 1 diabetes. J Autoimmun 2004;23:275-279
88. Barker JM, Barriga KJ, Yu L, Miao D, Erlich HA, Norris JM, Eisenbarth GS, Rewers M, Diabetes Autoimmunity Study in the Young. Prediction of autoantibody positivity and progression to type 1 diabetes: Diabetes Autoimmunity Study in the Young (DAISY). J Clin Endocrinol Metab 2004;89:3896-3902
89. Thomson G, Valdes AM, Noble JA, Kockum I, Grote MN, Najman J, Erlich HA, Cucca F, Pugliese A, Steenkiste A, Dorman JS, Caillat-Zucman S, Hermann R, Ilonen J, Lambert AP, Bingley PJ, Gillespie KM, Lernmark A, Sanjeevi CB, Rønningen KS, Undlien DE, Thorsby E, Petrone A, Buzzetti R, Koeleman BP, Roep BO, Saruhan-Direskeneli G, Uyar FA, Günoz H, Gorodezky C, Alaez C, Boehm BO, Mlynarski W, Ikegami H, Berrino M, Fasano ME, Dametto E, Israel S, Brautbar C, Santiago-Cortes A, Frazer de Llado T, She JX, Bugawan TL, Rotter JI, Raffel L, Zeidler A, Leyva-Cobian F, Hawkins BR, Chan SH, Castano L, Pociot F, Nerup J. Relative predispositional effects of HLA class II DRB1-DQB1 haplotypes and genotypes on type 1 diabetes: a meta-analysis. Tissue Antigens 2007;70: 110-127 (Pubitemid 47024833)
90. Barker JM, Triolo TM, Aly TA, Baschal EE, Babu SR, Kretowski A, Rewers MJ, Eisenbarth GS. Two single nucleotide polymorphisms identify the highest-risk diabetes HLA genotype: potential for rapid screening. Diabetes 2008;57:3152-3155
91. Baschal EE, Aly TA, Babu SR, Fernando MS, Yu L, Miao D, Barriga KJ, Norris JM, Noble JA, Erlich HA, Rewers MJ, Eisenbarth GS. HLADPB1*0402 protects against type 1A diabetic autoimmunity in the highest risk DR3-DQB1*0201/DR4-DQB1*0302 DAISY population. Diabetes 2007; 56:2405-2409 (Pubitemid 47358249)
92. Rewers M, Bugawan TL, Norris JM, Blair A, Beaty B, Hoffman M, McDuffie RS Jr, Hamman RF, Klingensmith G, Eisenbarth GS, Erlich HA. Newborn screening for HLA markers associated with IDDM: diabetes autoimmunity study in the young (DAISY). Diabetologia 1996;39:807-812 (Pubitemid 26228110)
93. Aly TA, Ide A, Jahromi MM, Barker JM, Fernando MS, Babu SR, Yu L, Miao D, Erlich HA, Fain PR, Barriga KJ, Norris JM, Rewers MJ, Eisenbarth GS. Extreme genetic risk for type 1A diabetes. Proc Natl Acad Sci U S A 2006;103:14074-14079 (Pubitemid 44452982)
94. Aly TA, Baschal EE, Jahromi MM, Fernando MS, Babu SR, Fingerlin TE, Kretowski A, Erlich HA, Fain PR, Rewers MJ, Eisenbarth GS. Analysis of single nucleotide polymorphisms identifies major type 1A diabetes locus telomeric of the major histocompatibility complex. Diabetes 2008;57:770-776
95. Nejentsev S, Howson JM, Walker NM, Szeszko J, Field SF, Stevens HE, Reynolds P, Hardy M, King E, Masters J, Hulme J, Maier LM, Smyth D, Bailey R, Cooper JD, Ribas G, Campbell RD, Clayton DG, Todd JA, Wellcome Trust Case Control Consortium. Localization of type 1 diabetes susceptibility to the MHC class I genes HLA-B and HLA-A. Nature 2007;450:887-892
96. Howson JM, Walker NM, Clayton D, Todd JA. Confirmation of HLA class II independent type 1 diabetes associations in the major histocompatibility complex including HLA-B and HLA-A. Diabetes Obes Metab 2009; 11(Suppl. 1):31-45
97. Baschal EE, Aly TA, Jasinski JM, Steck AK, Noble JA, Erlich HA, Eisenbarth GS, Type 1 Diabetes Genetics Consortium. Defining multiple common "completely" conserved major histocompatibility complex SNP haplotypes. Clin Immunol 2009;132:203-214
98. Raum D, Awdeh Z, Yunis EJ, Alper CA, Gabbay KH. Extended major histocompatibility complex haplotypes in type I diabetes mellitus. J Clin Invest 1984;74:449-454 (Pubitemid 14053992)
99. Aly TA, Eller E, Ide A, Gowan K, Babu SR, Erlich HA, Rewers MJ, Eisenbarth GS, Fain PR. Multi-SNP analysis of MHC region: remarkable conservation of HLA-A1-B8-DR3 haplotype. Diabetes 2006;55:1265-1269 (Pubitemid 44195363)
100. Bilbao JR, Calvo B, Aransay AM, Martin-Pagola A, Perez de Nanclares G, Aly TA, Rica I, Vitoria JC, Gaztambide S, Noble J, Fain PR, Awdeh ZL, Alper CA, Castaño L. Conserved extended haplotypes discriminate HLADR3-homozygous Basque patients with type 1 diabetes mellitus and celiac disease. Genes Immun 2006;7:550-554 (Pubitemid 44636906)
101. Baschal EE, Aly TA, Jasinski JM, Steck AK, Johnson KN, Noble JA, Erlich HA, Eisenbarth GS. The frequent and conserved DR3-B8-A1 extended haplotype confers less diabetes risk than other DR3 haplotypes. Diabetes Obes Metab 2009;11(Suppl .1):25-30
102. International Multiple Sclerosis Genetics Consortium, Hafler DA, Compston A, Sawcer S, Lander ES, Daly MJ, De Jager PL, de Bakker PI, Gabriel SB, Mirel DB, Ivinson AJ, Pericak-Vance MA, Gregory SG, Rioux JD, McCauley JL, Haines JL, Barcellos LF, Cree B, Oksenberg JR, Hauser SL. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 2007;357:851-862 (Pubitemid 47347319)
103. Grant SF, Qu HQ, Bradfield JP, Marchand L, Kim CE, Glessner JT, Grabs R, Taback SP, Frackelton EC, Eckert AW, Annaiah K, Lawson ML, Otieno FG, Santa E, Shaner JL, Smith RM, Skraban R, Imielinski M, Chiavacci RM, Grundmeier RW, Stanley CA, Kirsch SE, Waggott D, Paterson AD, Monos DS, DCCT/EDIC Research Group, Polychronakos C, Hakonarson H. Follow-up analysis of genome-wide association data identifies novel loci for type 1 diabetes. Diabetes 2009;58:290-295
104. Pugliese A, Zeller M, Fernandez A Jr, Zalcberg LJ, Bartlett RJ, Ricordi C, Pietropaolo M, Eisenbarth GS, Bennett ST, Patel DD. The insulin gene is transcribed in the human thymus and transcription levels correlated with allelic variation at the INS VNTR-IDDM2 susceptibility locus for type 1 diabetes. Nat Genet 1997;15:293-297 (Pubitemid 27098726)
105. Vafiadis P, Bennett ST, Todd JA, Nadeau J, Grabs R, Goodyer CG, Wickramasinghe S, Colle E, Polychronakos C. Insulin expression in human thymus is modulated by INS VNTR alleles at the IDDM2 locus. Nat Genet 1997;15:289-292 (Pubitemid 27098725)
106. Zoledziewska M, Perra C, Orrù V, Moi L, Frongia P, Congia M, Bottini N, Cucca F. Further evidence of a primary, causal association of the PTPN22 620W variant with type 1 diabetes. Diabetes 2008;57:229-234
107. Bottini N, Musumeci L, Alonso A, Rahmouni S, Nika K, Rostamkhani M, MacMurray J, Meloni GF, Lucarelli P, Pellecchia M, Eisenbarth GS, Comings D, Mustelin T. A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nat Genet 2004;36:337-338 (Pubitemid 38437254)
108. Vang T, Congia M, Macis MD, Musumeci L, Orrú V, Zavattari P, Nika K, Tautz L, Taskén K, Cucca F, Mustelin T, Bottini N. Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant. Nat Genet 2005;37:1317-1319 (Pubitemid 41722185)
109. Liu S, Wang H, Jin Y, Podolsky R, Reddy MV, Pedersen J, Bode B, Reed J, Steed D, Anderson S, Yang P, Muir A, Steed L, Hopkins D, Huang Y, Purohit S, Wang CY, Steck AK, Montemari A, Eisenbarth G, Rewers M, She JX. IFIH1 polymorphisms are significantly associated with type 1 diabetes and IFIH1 gene expression in peripheral blood mononuclear cells. Hum Mol Genet 2009;18:358-365
110. Field SF, Howson JM, Smyth DJ, Walker NM, Dunger DB, Todd JA. Analysis of the type 2 diabetes gene, TCF7L2, in 13,795 type 1 diabetes cases and control subjects. Diabetologia 2007;50:212-213 (Pubitemid 46035870)
111. Yu J, Steck AK, Babu S, Yu L, Miao D, McFann K, Hutton J, Eisenbarth GS, Klingensmith G. Single nucleotide transcription factor 7-like 2 (TCF7L2) gene polymorphisms in antiislet autoantibody-negative patients at onset of diabetes. J Clin Endocrinol Metab 2009;94:504-510
112. Cervin C, Lyssenko V, Bakhtadze E, Lindholm E, Nilsson P, Tuomi T, Cilio CM, Groop L. Genetic similarities between latent autoimmune diabetes in adults, type 1 diabetes, and type 2 diabetes. Diabetes 2008;57:1433-1437
113. Steck AK, Eisenbarth GS. Genetic similarities between latent autoimmune diabetes and type 1 and type 2 diabetes. Diabetes 2008;57:1160-1162
114. Steck AK, Liu SY, McFann K, Barriga KJ, Babu SR, Eisenbarth GS, Rewers MJ, She JX. Association of the PTPN22/LYP gene with type 1 diabetes. Pediatr Diabetes 2006;7:274-278 (Pubitemid 44593928)
115. Bjørnvold M, Undlien DE, Joner G, Dahl-Jørgensen K, Njølstad PR, Akselsen HE, Gervin K, Rønningen KS, Stene LC. Joint effects of HLA INS, PTPN22 and CTLA4 genes on the risk of type 1 diabetes. Diabetologia 2008;51:589-596
116. Gillespie KM, Bain SC, Barnett AH, Bingley PJ, Christie MR, Gill GV, Gale EA. The rising incidence of childhood type 1 diabetes and reduced contribution of high-risk HLA haplotypes. Lancet 2004;364:1699-1700
117. Vehik K, Hamman RF, Lezotte D, Norris JM, Klingensmith GJ, Rewers M, Dabelea D. Trends in high-risk HLA susceptibility genes among Colorado youth with type 1 diabetes. Diabetes Care 2008;31:1392-1396
118. Barker JM, Goehrig SH, Barriga K, Hoffman M, Slover R, Eisenbarth GS, Norris JM, Klingensmith GJ, Rewers M, DAISY study. Clinical characteristics of children diagnosed with type 1 diabetes through intensive screening and follow-up. Diabetes Care 2004;27:1399-1404
119. Patterson CC, Dahlquist GG, Gyürüs E, Green A, Soltész G, EURODIAB Study Group. Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-20: a multicentre prospective registration study. Lancet 2009;373:2027-2033
120. Harjutsalo V, Sjöberg L, Tuomilehto J. Time trends in the incidence of type 1 diabetes in Finnish children: a cohort study. Lancet 2008;371:1777-1782 (Pubitemid 351697953)
121. Writing Group for the SEARCH for Diabetes in Youth Study Group, Dabelea D, Bell RA, D'Agostino RB Jr, Imperatore G, Johansen JM, Linder B, Liu LL, Loots B, Marcovina S, Mayer-Davis EJ, Pettitt DJ, Waitzfelder B. Incidence of diabetes in youth in the United States. JAMA 2007;297: 2716-2724
122. Bach JF. The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med 2002;347:911-920
123. Gale EA. A missing link in the hygiene hypothesis? Diabetologia 2002;45: 588-594
124. Wen L, Ley RE, Volchkov PY, Stranges PB, Avanesyan L, Stonebraker AC, Hu C, Wong FS, Szot GL, Bluestone JA, Gordon JI, Chervonsky AV. Innate immunity and intestinal microbiota in the development of type 1 diabetes. Nature 2008;455:1109-1113
125. Gale EA. To boldly go - or to go too boldly? The accelerator hypothesis revisited. Diabetologia 2007;50:1571-1575
126. Fourlanos S, Harrison LC, Colman PG. The accelerator hypothesis and increasing incidence of type 1 diabetes. Curr Opin Endocrinol Diabetes Obes 2008;15:321-325
127. Raj SM, Howson JM, Walker NM, Cooper JD, Smyth DJ, Field SF, Stevens HE, Todd JA. No association of multiple type 2 diabetes loci with type 1 diabetes. Diabetologia 2009;52:2109-2116
128. Fourlanos S, Narendran P, Byrnes GB, Colman PG, Harrison LC. Insulin resistance is a risk factor for progression to type 1 diabetes. Diabetologia 2004;47:1661-1667 (Pubitemid 40022398)
129. Li Q, Xu B, Michie SA, Rubins KH, Schreriber RD, McDevitt HO. Interferon-alpha initiates type 1 diabetes in nonobese diabetic mice. Proc Natl Acad Sci U S A 2008;105:12439-12444
130. Schreuder TC, Gelderblom HC, Weegink CJ, Hamann D, Reesink HW, Devries JH, Hoekstra JB, Jansen PL: High incidence of type 1 diabetes mellitus during or shortly after treatment with pegylated interferon alpha for chronic hepatitis C virus infection. Liver Int 2008;28:39-46
131. Weintrob N, Sprecher E, Israel S, Pinhas-Hamiel O, Kwon OJ, Bloch K, Abramov N, Arbel A, Josefsberg Z, Brautbar C, Vardi P. Type 1 diabetes environmental factors and correspondence analysis of HLA class II genes in the Yemenite Jewish community in Israel. Diabetes Care 2001;24:650-653 (Pubitemid 32888843)
132. Ito Y, Nieda M, Uchigata Y, Nishimura M, Tokunaga K, Kuwata S, Obata F, Tadokoro K, Hirata Y, Omori Y. Recognition of human insulin in the context of HLA-DRB1*0406 products by T cells of insulin autoimmune syndrome patients and healthy donors. J Immunol 1993;151:5770-5776 (Pubitemid 23332386)
133. Uchigata Y, Hirata Y, Omori Y, Iwamoto Y, Tokunaga K. Worldwide differences in the incidence of insulin autoimmune syndrome (Hirata disease) with respect to the evolution of HLA-DR4 alleles. Hum Immunol 2000;61:154-157 (Pubitemid 30075237)
134. Vardi P, Brik R, Barzilai D, Lorber M, Scharf Y. Frequent induction of insulin autoantibodies by D-penicillamine in patients with rheumatoid arthritis. J Rheumatol 1992;19:1527-1530
135. Furukawa N, Miyamura N, Nishida K, Motoshima H, Taketa K, Araki E. Possible relevance of alpha lipoic acid contained in a health supplement in a case of insulin autoimmune syndrome. Diabetes Res Clin Pract 2007;75:366-367 (Pubitemid 46074207)
136. Akerblom HK, Virtanen SM, Ilonen J, Savilahti E, Vaarala O, Reunanen A, Teramo K, Hämäläinen AM, Paronen J, Riikjärv MA, Ormisson A, Ludvigsson J, Dosch HM, Hakulinen T, Knip M, National TRIGR Study Groups. Dietary manipulation of beta cell autoimmunity in infants at increased risk of type 1 diabetes: a pilot study. Diabetologia 2005;48:829-837
137. Poole JA, Barriga K, Leung DY, Hoffman M, Eisenbarth GS, Rewers M, Norris JM. Timing of initial exposure to cereal grains and the risk of wheat allergy. Pediatrics 2006;117:2175-2182 (Pubitemid 46071263)
138. Ziegler AG, Schmid S, Huber D, Hummel M, Bonifacio E. Early infant feeding and risk of developing type 1 diabetes-associated autoantibodies. JAMA 2003;290:1721-1728 (Pubitemid 37430622)
139. Norris JM, Yin X, Lamb MM, Barriga K, Seifert J, Hoffman M, Orton HD, Barón AE, Clare-Salzler M, Chase HP, Szabo NJ, Erlich H, Eisenbarth GS, Rewers M. Omega-3 polyunsaturated fatty acid intake and islet autoimmunity in children at increased risk for type 1 diabetes. JAMA 2007;298: 1420-1428 (Pubitemid 47481608)
140. Stene LC, Joner G, Norwegian Childhood Diabetes Study Group. Use of cod liver oil during the first year of life is associated with lower risk of childhood-onset type 1 diabetes: a large, population-based, case-control study. Am J Clin Nutr 2003;78:1128-1134 (Pubitemid 39663453)
141. Oresic M, Simell S, Sysi-Aho M, Näntö -Salonen K, Seppänen-Laakso T, Parikka V, Katajamaa M, Hekkala A, Mattila I, Keskinen P, Yetukuri L, Reinikainen A, Lähde J, Suortti T, Hakalax J, Simell T, Hyöty H, Veijola R, Ilonen J, Lahesmaa R, Knip M, Simell O. Dysregulation of lipid and amino acid metabolism precedes islet autoimmunity in children who later progress to type 1 diabetes. J Exp Med 2008;205:2975-2984
142. Wang X, Jia S, Geoffrey R, Alemzadeh R, Ghosh S, Hessner MJ. Identification of a molecular signature in human type 1 diabetes mellitus using serum and functional genomics. J Immunol 2008;180:1929-1937
143. Salminen KK, Vuorinen T, Oikarinen S, Helminen M, Simell S, Knip M, Ilonen J, Simell O, Hyöty H. Isolation of enterovirus strains from children with preclinical type 1 diabetes. Diabet Med 2004;21:156-164 (Pubitemid 38221815)
144. Graves PM, Rotbart HA, Nix WA, Pallansch MA, Erlich HA, Norris JM, Hoffman M, Eisenbarth GS, Rewers M. Prospective study of enteroviral infections and development of beta-cell autoimmunity: Diabetes Autoimmunity Study in the Young (DAISY). Diabetes Res Clin Pract 2003;59: 51-61 (Pubitemid 35461910)
145. Guberski DL, Thomas VA, Shek WR, Like AA, Handler ES, Rossini AA, Wallace JE, Welsh RM. Induction of type I diabetes by Kilham's rat virus in diabetes-resistant BB/Wor rats. Science 1991;254:1010-1013
146. Blankenhorn EP, Descipio C, Rodemich L, Cort L, Leif JH, Greiner DL, Mordes JP: Refinement of the Iddm4 diabetes susceptibility locus reveals TCRVbeta4 as a candidate gene. Ann N Y Acad Sci 2007;1103:128-131 (Pubitemid 46791120)
147. Zipris D, Lien E, Nair A, Xie JX, Greiner DL, Mordes JP, Rossini AA. TLR9-signaling pathways are involved in Kilham rat virus-induced autoimmune diabetes in the biobreeding diabetes-resistant rat. J Immunol 2007;178:693-701 (Pubitemid 46095141)
148. Devendra D, Jasinski J, Melanitou E, Nakayama M, Li M, Hensley B, Paronen J, Moriyama H, Miao D, Eisenbarth GS, Liu E. Interferon-α as a mediator of polyinosinic:polycytidylic acid-induced type 1 diabetes. Diabetes 2005;54:2549-2556 (Pubitemid 41233575)
149. Bottazzo GF, Florin-Christensen A, Doniach D. Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet 1974;2:1279-1283
150. Yu L, Eisenbarth GS. Humoral autoimmunity in type 1 diabetes: cellular, molecular and clinical immunology [article online], 2009. Available from http://www.uchsc.edu/misc/diabetes/books.html. Accessed 2 February 2010
151. Wenzlau JM, Moua O, Sarkar SA, Yu L, Rewers M, Eisenbarth GS, Davidson HW, Hutton JC. SlC30A8 is a major target of humoral autoimmunity in type 1 diabetes and a predictive marker in prediabetes. Ann N Y Acad Sci 2008;1150:256-259
152. Wenzlau JM, Liu Y, Yu L, Moua O, Fowler KT, Rangasamy S, Walters J, Eisenbarth GS, Davidson HW, Hutton JC. A common nonsynonymous single nucleotide polymorphism in the SLC30A8 gene determines ZnT8 autoantibody specificity in type 1 diabetes. Diabetes 2008;57:2693-2697
153. Bingley PJ, Christie MR, Bonifacio E, Bonfanti R, Shattock M, Fonte MT, Bottazzo GF, Gale EA. Combined analysis of autoantibodies improves prediction of IDDM in islet cell antibody-positive relatives. Diabetes 1994;43:1304-1310
154. Achenbach P, Koczwara K, Knopff A, Naserke H, Ziegler AG, Bonifacio E. Mature high-affinity immune responses to (pro)insulin anticipate the autoimmune cascade that leads to type 1 diabetes. J Clin Invest 2004;114: 589-597 (Pubitemid 39572109)
155. Oak S, Gilliam LK, Landin-Olsson M, Törn C, Kockum I, Pennington CR, Rowley MJ, Christie MR, Banga JP, Hampe CS: The lack of anti-idiotypic antibodies, not the presence of the corresponding autoantibodies to glutamate decarboxylase, defines type 1 diabetes. Proc Natl Acad Sci U S A 2008;105:5471-5476 (Pubitemid 351753887)
156. Wang J, Miao D, Babu S, Yu J, Barker J, Klingensmith G, Rewers M, Eisenbarth GS, Yu L. Prevalence of autoantibody-negative diabetes is not rare at all ages and increases with older age and obesity. J Clin Endocrinol Metab 2007;92:88-92 (Pubitemid 46075008)
157. Murphy R, Ellard S, Hattersley AT. Clinical implications of a molecular genetic classification of monogenic beta-cell diabetes. Nat Clin Pract Endocrinol Metab 2008;4:200-213 (Pubitemid 351430925)
158. Vardi P, Ziegler AG, Mathews JH, Dib S, Keller RJ, Ricker AT, Wolfsdorf JI, Herskowitz RD, Rabizadeh A, Eisenbarth GS. Concentration of insulin autoantibodies at onset of type I diabetes: inverse log-linear correlation with age. Diabetes Care 1988;11:736-739
159. Achenbach P, Ziegler AG. Diabetes-related antibodies in euglycemic subjects. Best Pract Res Clin Endocrinol Metab 2005;19:101-117
160. Achenbach P, Bonifacio E, Williams AJ, Ziegler AG, Gale EA, Bingley PJ, ENDIT Group: Autoantibodies to IA-2beta improve diabetes risk assessment in high-risk relatives. Diabetologia 2008;51:488-492
161. Liu E, Eisenbarth GS. Accepting clocks that tell time poorly: fluid-phase versus standard ELISA autoantibody assays. Clin Immunol 2007;125:120-126 (Pubitemid 47562903)
162. Brooking H, Ananieva-Jordanova R, Arnold C, Amoroso M, Powell M, Betterle C, Zanchetta R, Furmaniak J, Smith BR. A sensitive non-isotopic assay for GAD65 autoantibodies. Clin Chim Acta 2003;331:55-59 (Pubitemid 36412025)
163. Bingley PJ, Bonifacio E, Mueller PW. Diabetes Antibody Standardization Program: first assay proficiency evaluation. Diabetes 2003;52:1128-1136 (Pubitemid 36523346)
164. Barker JM, McFann K, Harrison LC, Fourlanos S, Krischer J, Cuthbertson D, Chase HP, Eisenbarth GS, DPT-1 Study Group. Pre-type 1 diabetes dysmetabolism: maximal sensitivity achieved with both oral and intravenous glucose tolerance testing. J Pediatr 2007;150:31-36
165. Sosenko JM, Palmer JP, Rafkin-Mervis L, Krischer JP, Cuthbertson D, Matheson D, Skyler JS: Glucose and C-peptide changes in the perionset period of type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 2008;31:2188-2192
166. Stene LC, Barriga K, Hoffman M, Kean J, Klingensmith G, Norris JM, Erlich HA, Eisenbarth GS, Rewers M. Normal but increasing hemoglobin A1c levels predict progression from islet autoimmunity to overt type 1 diabetes: Diabetes Autoimmunity Study in the Young (DAISY). Pediatr Diabetes 2006;7:247-253 (Pubitemid 44593924)
167. Allison JP, Havran WL. The immunobiology of T cells with invariant gamma delta antigen receptors. Annu Rev Immunol 1991;9:679-705
168. Palmer JP, Fleming GA, Greenbaum CJ, Herold KC, Jansa LD, Kolb H, Lachin JM, Polonsky KS, Pozzilli P, Skyler JS, Steffes MW. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001. Diabetes 2004;53:250-264
169. Meier JJ, Bhushan A, Butler AE, Rizza RA, Butler PC. Sustained beta cell apoptosis in patients with long-standing type 1 diabetes: indirect evidence for islet regeneration? Diabetologia 2005;48:2221-2228
170. Butler PC, Meier JJ, Butler AE, Bhushan A: The replication of beta cells in normal physiology, in disease and for therapy 1. Nat Clin Pract Endocrinol Metab 2007;3:758-768
171. Gianani R, Campbell-Thompson M, Sarkar SA, Wasserfall C, Pugliese A, Solis JM, Kent S, Hering B, West E, Steck A, Bonner-Weir S, Atkinson MA, Coppieters K, von Herrath M, Eisenbarth GS. Dimorphic histopathology of long-standing childhood-onset diabetes. Diabetologia 2010. [Epub ahead of print]
172. Balasubramanyam A, Nalini R, Hampe CS, Maldonado M. Syndromes of ketosis-prone diabetes mellitus. Endocr Rev 2008;29:292-302
173. Foulis AK, Clark A: Pathology of the pancreas in diabetes mellitus. In Joslin's Diabetes Mellitus. 13th ed. Kahn CR, Weir GC, Eds. Philadelphia, Lea & Febiger, 1994, p. 265-281
174. Willcox A, Richardson SJ, Bone AJ, Foulis AK, Morgan NG. Analysis of islet inflammation in human type 1 diabetes. Clin Exp Immunol 2009;155: 173-181
175. Herold KC, Gitelman SE, Masharani U, Hagopian W, Bisikirska B, Donaldson D, Rother K, Diamond B, Harlan DM, Bluestone JA. A single course of anti-CD3 monoclonal antibody hOKT3γ1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 2005;54:1763-1769 (Pubitemid 40770766)
176. Keymeulen B, Vandemeulebroucke E, Ziegler AG, Mathieu C, Kaufman L, Hale G, Gorus F, Goldman M, Walter M, Candon S, Schandene L, Crenier L, De Block C, Seigneurin JM, De Pauw P, Pierard D, Weets I, Rebello P, Bird P, Berrie E, Frewin M, Waldmann H, Bach JF, Pipeleers D, Chatenoud L. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005;352:2598-2608 (Pubitemid 41007846)
177. Skyler JS, Brown D, Chase HP, Collier E, Cowie C, Eisenbarth GS, Fradkin J, Grave G, Greenbaum C, Jackson RA, Kaufman FR, Krischer JP, Marks JB, Palmer JP, Ricker A, Schatz DA, Wilson D, Winter WE, Wolfsdorf J, Zeidler A, Dickler H, Eastman RC, Maclaren NK, Malone JI, Robertson PR, Skyler JS, Krischer JP, Wolfsdorf J, Cowie C, Palmer JP, Greenbaum C, Cuthbertson D, Rafkin-Mervis LM, Kaufman FR, Chase HP, Palmer JP, Chase HP, Cowie C, Fradkin J, Eisenbarth GS, Greenbaum C, Herold K, Kaufman FR, Krischer JP, Marks JB, Rafkin-Mervis L, Schatz DA, Skyler JS, Aneju B, Conboy D, Cook R, Dennis MA, Finney L, Harris S, Matheson D, McCulloch-Olsen M, Smith T, Valenzuela J, Vega N, Crofford OB, DeMets D, Lachin JM, Nerup J, Rossini A, Schiffrin A, Steffes M, Tsiatis A, Zinman B: Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med 2002;346:1685B-1691B
178. Bingley PJ, Gale EA, European Nicotinamide Diabetes Intervention Trial (ENDIT) Group. Progression to type 1 diabetes in islet T cell antibody-positive relatives in the European Nicotinamide Diabetes Intervention Trial: the role of additional immune, genetic and metabolic markers of risk. Diabetologia 2006;49:881-890
179. Ludvigsson J, Faresjö M, Hjorth M, Axelsson S, Chéramy M, Pihl M, Vaarala O, Forsander G, Ivarsson S, Johansson C, Lindh A, Nilsson NO, Aman J, Ortqvist E, Zerhouni P, Casas R: GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med 2008;359:1909-1920
180. Herold KC, Gitelman S, Greenbaum C, Puck J, Hagopian W, Gottlieb P, Sayre P, Bianchine P, Wong E, Seyfert-Margolis V, Bourcier K, Bluestone JA, Immune Tolerance Network ITN007AI Study Group. Treatment of patients with new onset type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years. Clin Immunol 2009;132:166-173
181. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, Becker DJ, Gitelman SE, Goland R, Gottlieb PA, Marks JB, McGee PF, Moran AM, Raskin P, Rodriguez H, Schatz DA, Wherrett D, Wilson DM, Lachin JM, Skyler JS, Type 1 Diabetes TrialNet Anti-CD20 Study Group. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 2009;361:2143-2152
182. El Fassi D, Banga JP, Gilbert JA, Padoa C, Hegedüs L, Nielsen CH. Treatment of Graves' disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies. Clin Immunol 2009;130: 252-258
183. Bresson D, von Herrath M. Moving towards efficient therapies in type 1 diabetes: to combine or not to combine? Autoimmun Rev 2007;6:315-322
184. Maniatis AK, Yu L, Miao D, Nelson K, Eisenbarth GS. Rapid assays for detection of anti-islet autoantibodies: implications for organ donor screening. J Autoimmun 2001;16:71-76 (Pubitemid 32174176)
185. Gianani R, Putnam A, Still T, Yu L, Miao D, Gill RG, Beilke J, Supon P, Valentine A, Iveson A, Dunn S, Eisenbarth GS, Hutton J, Gottlieb P, Wiseman A. Initial results of screening of non-diabetic organ donors for expression of islet autoantibodies. J Clin Endocrinol Metab 2006;91:1855-1861